drugset / Trial / NCT03955679

AveXis Managed Access Program Cohort for Access to AVXS-101

NCT03955679 ↗

Expanded access Approved for marketing United BioSource, LLC AveXis, Inc. · collab

Summary

The purpose of this Cohort Treatment Protocol will allow access to AVXS-101 for eligible patients diagnosed with SMA.

Timeline

Start
—
Primary completion
—
Completion
—

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject AVXS-101 Gene therapy (AAV / viral vector) — Intravenous